Company Contact Email:
master@htpharm.com
Vision/Mission
We have enhanced our product competitiveness by adopting a quality-first policy, supplying over 95% of our products to overseas markets, including Europe. With the rapid growth expected in the carbapenem antibiotics market, we believe our future is bright.
We continue to work toward becoming a leading global company for drug substance. Using our advanced technology and years of experience, we focus on developing high-quality antibiotic drug substance. At High Tech Pharm, we are committed to making and supplying the world best raw materials for medicine. We will keep challenging ourselves to create the highest quality carbapenem antibiotics
History
1998 Company Founded, Daeso Plant (High Tech Pharm)
2007 Established the R & D Center
2010 Listed on the KOSDAQ
2018 Chungju Plant Established, GMP Inspection & Approval (MFDS)
2021 GMP Inspection & Approval (USFDA), 2nd GMP Inspection & Approval (MFDS)
2023 2nd GMP Inspection & Approval (USFDA), GMP Inspection & Approval (EU)
2024 3rd GMP Inspection & Approval (MFDS)
2021~2024 From 2001 to 2024, Daeso plant was inspected and approved by the MFDS, PMDA(JAPAN), and USFDA.
Products/Services
Imipenem Sterile
Imipenem Crude
Ertapenem Sodium
Blended Imipenem-Cilastatin Sterile
Doripenem
Tebipenem
Industry
Pharmaceutical Industry
Location
(Chung-ju) 12, Cheomdansaneop 6-ro, Daesowon-myeon, Chungju-si, Chungcheongbuk-do, 27466, Korea
(Daeso) 280, Sinnae-ro, Daeso-myeon, Eumseong-gun, Chungcheongbuk-do, 27663, Korea
Website
Employees
130 (as of december 2024)